The risk of stent thrombosis is multifactorial and may remain for long  by Shite, Junya
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he  risk  of  stent  thrombosis  is  multifactorial  and  may  remain  for  long
endothelial dysfunction may  play a part in thrombogenicity. How-
ever, we have no feasible method to visualize endothelial cells
and to evaluate endothelial function in clinical practice. Furthereywords:
tent thrombosis
ptical coherence tomography
ngioscopy
Stent thrombosis (ST) seldom happens, however, once this
omplication occurs, it may  result in life-threatening catastrophic
vents such as trans-mural myocardial infarction or sudden cardiac
eath. We  should clarify the mechanism of ST to prevent serious
omplications. In the Bern-Rotterdam registry, at three years, the
umulative incidence of angiographic ST was 2.9%, with early stent
hrombosis occurring in 60% and late stent thrombosis in 40%. Late
tent thrombosis occurred steadily at a constant rate of 0.6% per
ear up to three years after stent implantation [1]. From the SCAAR
egistry, the cumulative rates of ST at two years for ﬁrst-generation
rug-eluting stents (DES) (sirolimus-, paclitaxel-, and Endeavor®
otarolimus-eluting stents, Medtronic, Minneapolis, MN,  USA) was
.3% and second-generation DES (everolimus- and Endeavor® Res-
lute zotarolimus-eluting stents, Medtronic) was 0.6% (a 43% lower
isk of deﬁnite ST compared with ﬁrst-generation DES) [2].
eﬁnition of ST
The deﬁnition of ST was proposed by the Academic Research
onsortium, as Deﬁnite: angiographic conﬁrmation of a thrombus
hat originates in the stent or in the segment 5 mm proximal or dis-
al to the stent, with or without vessel occlusion, which is associated
ith acute onset of ischemic symptoms at rest or electorcardio-
raphic signs of acute ischemia or typical rise and fall of in cardiac
iomarkers within 48 h of angiography or pathologic conﬁrma-
ion of ST determined at autopsy or from tissue obtained following
hrombectomy [3]. The case reported by Ishikawa et al. [4] is con-
idered as deﬁnite ST, because emergency coronary angiography
howed a total occlusion at the overlapping site of the 2 paclitaxel-
luting stents (PESs) with thrombus resulting in acute myocardial
nfarction.
echanism of STST may  occur acutely (within 24 h), subacutely (within 30 days),
ate (within one year), or very late (more than one year) after stent
lacement. The mechanism for ST involves multiple factors, such as
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cessation of dual antiplatelet therapy (DAPT) [5]. We  consider that
early ST is mainly related to procedural factors such as stent under
expansion or stent edge dissection, and late to very late ST is related
to stent fracture [6], incomplete neointimal coverage (Fig. 1), atyp-
ical vessel reaction [7], neo-atherosclerosis in neointima [8], and
cessation of DAPT (Table 1). The timing of ST of the reported case
was 17 months after percutaneous coronary intervention. Thus it
is categorized as very late ST. In this case, surprisingly, full neoin-
timal coverage was observed, and there were no ﬁndings of stent
malapposition and also DAPT had been continued. The only abnor-
mal  ﬁnding was  the high range of normalized standard deviation
values in optical coherence tomography (OCT) image of neoin-
tima suggesting abnormal immature neointima. According to my
experience, OCT ﬁndings of homogeneous high intensity neoin-
tima show generally matured white neointima by angioscopy, and
that of heterogeneous neointima was yellow neointima mixed with
red thrombus (Fig. 2). The authors speculated that allergic action
in neointima had thrombogenicity and formed thrombus involv-
ing inﬂammatory cells. I estimate that lack of endothelial cells orFig. 1. Optical coherence tomography ﬁndings of mural thrombus (6 o’clock) at the
lesion with incomplete neointimal coverage.
vier Ltd. All rights reserved.
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Fig. 2. Optical coherence tomography (OCT) ﬁnding of homogeneous high-intensity neo
of  heterogeneous low-intensity neoitima corresponding to yellow neointima mixed with
color  in this ﬁgure legend, the reader is referred to the web  version of this article.)
Table 1
Possible mechanisms of stent thrombosis (ST).
Early ST
Stent under expansion
Stent edge dissection
Stent malapposition
Regression of thrombus resulting in malapposition
Insufﬁcient effect of antiplatelet drug
Late to very late ST
Neointimal proliferation results in restenosis
Stent fracture
Incomplete neointimal coverage
Neointimal inﬂammation
Endothelial dysfunction
Late acquired malapposition or inter-strut hollow due to
Peri-stent inﬂammation
Vessel positive remodeling due to vessel inﬂammation
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Atherosclerosis in neointima
Cessation of dual antiplatelet therapy
evelopment of feasible modality is required to evaluate the throm-
ogenicity of neointima.
linical implication of this case report
Disappointingly, according to this case report, even though full
eointimal coverage was observed by OCT, we may  not say that the
isk of ST had disappeared. Also, even though DAPT was continued,
T may  happen. The optimal duration of DAPT remains ambiguous
nd we should always be cautious about ST. To whom we  can say
hat you are safe from ST remains to be clariﬁed.eferences
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